A phase I trial of BAY 43-9006 (sorafenib) and bevacizumab in refractory solid tumors with biologic and proteomic analysis.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Bevacizumab (Primary) ; Sorafenib (Primary)
- Indications Prostate cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 23 Jul 2012 Actual end date (1 Jul 2012) added as reported by ClinicalTrials.gov.
- 23 Jul 2012 Actual end date (1 Jul 2012) added as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.